A B S T R A C T
A human induced pluripotent stem cell (iPSC) line was generated from fibroblasts of a patient with propionic acidemia that has a homozygous mutation (c.1218_1231del14ins12 (p.G407 fs)) in the PCCB gene. Reprogramming factors OCT3/4, SOX2, KLF4 and c-MYC were delivered using a non-integrative method based on the Sendai virus. Once established, iPSCs have shown full pluripotency, differentiation capacity and genetic stability. The generated iPSC line represents a useful tool to study the pathomechanisms underlying the deficiency.
Resource 
Resource utility
The pathophysiology of propionic acidemia is not completely understood and its treatment currently is not satisfactory. In order to investigate underlying cellular pathological mechanisms and to test potential therapeutic compounds, we have established an iPSC line with a homozygous mutation in the PCCB gene. A. López-Márquez, et al. Stem Cell Research 38 (2019) 101469 in either the PCCA or PCCB genes, encoding both subunits of the mitochondrial propionyl-CoA carboxylase (PCC) enzyme, that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA, which eventually enters the Krebs cycle as succinyl-CoA (Richard et al., 2015) . Fibroblasts from a homozygous PA patient carrying the previously described c.1218_1231del14ins12 (p.G407 fs) mutation in the PCCB gene (Tahara et al., 1990) were reprogrammed using the CytoTune™ iPS Reprogramming kit delivering the four human reprogramming factors OCT3/4, SOX2, c-MYC and KLF4 (Takahashi et al., 2007) . The iPSC line PCCB10-FiPS4F1 (UAMi004-A) (PCCB10-1 in figures for short) displayed a typical round shape ESC-like morphology and growth behaviour on feeder layers and on feeder-free layers (Fig. 1A , Table 1 ). Clearance of the vectors and of the exogenous reprogramming factor genes was observed by RT-PCR after 8 culture passages (Fig. 1B) . Expression of key pluripotency genes was observed at protein level by immunocytochemistry (transcription factors OCT4, NANOG and SOX2, and surface markers SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81) (Fig. 1C , Table 1 ) and flow cytometry analysis ( Fig. 1D , Table 1 ). The iPSC line displayed a normal karyotype (46, XX) after more than twenty culture passages (Fig. 1E ). The cells had the capacity to form derivatives of all three germ layers (endoderm, mesoderm and ectoderm) upon embryoid body differentiation ( Fig. 1F , Table 1 ). Mycoplasma testing by PCR revealed a negative result ( Supplementary Fig. S1A ). We confirmed the presence of the mutation in the iPSC line in homozygous fashion by Sanger sequencing ( Supplementary Fig. S1B ); and we also confirmed by DNA fingerprinting analysis that the line was derived from the patient fibroblasts.
Resource details

Materials and methods
Non-integrative reprogramming of mutant PCCB fibroblasts into iPSC
The present study included available fibroblasts from a PA patient with defects in the PCCB gene. Experimental protocols were approved by the Institutional Ethical Committee of the Universidad Autónoma de Madrid according to Spanish and European Union legislation, and the informed consent was obtained from the legal care-givers. Fibroblasts were reprogrammed using the CytoTune™ iPS Reprogramming kit (ThermoFisher Scientific) following the manufacturer's instructions. iPSCs were maintained and expanded both on feeder layers and on feeder-free layers as previously described (Alonso-Barroso et al., 2017).
Detection of Sendai virus genome and transgenes
After 8 passages, iPSC line was tested for Sendai virus (SeV) residues as described (Alonso- Barroso et al., 2017) . PCR was performed using the primers indicated in Table 2 and following the instructions as recommended by the manufacturer. In Fig. 1 panel B : C+: transduced cell pool at passage zero; C-: non-template control.
Immunofluorescence analysis
iPSC were grown on feeder-free layers on 15 μ-Slide 8 well culture plates (Ibidi) and fixed with Formaline Solution 10% (Sigma-Aldrich). Immunofluorescence analysis was performed as previously described (Alonso-Barroso et al., 2017) . In Fig. 1 scale bars: 100 μm.
Flow cytometry analysis
We analysed the pluripotency-associated markers SSEA-3 and SSEA-4 by flow cytometry as described (Alonso-Barroso et al., 2017) . Unstained iPSCs and the corresponding isotype antibodies were used as negative controls to exclude data from non-specific fluorescence.
In vitro differentiation
iPSCs were detached with Accutase™ into a single cell suspension and resuspended in mTESR™1 medium (StemCell™ Technologies) with 10 μM Rock inhibitor (StemCell™ Technologies). Embryoid body formation was induced by seeding 20,000-30,000 iPS cells in 120 μl of mTESR™1 medium in each well of 96-well v-bottom, low attachment plates (Deltalab). In vitro differentiation was performed as described (Alonso-Barroso et al., 2017).
Mycoplasma detection
Cells were screened for mycoplasma contamination by PCR (Uphoff & Drexler, 2014) . A positive sample with mycoplasma was used as a control. In Supplementary Fig. S1A : positive control (C+).
Mutation analysis
Genomic DNA from patient-derived fibroblasts and iPSCs was isolated using MagNA Pure Compact DNA Isolation kit and MagNA Pure Compact instrument (Roche). Subsequently, amplification by PCR of the PCCB region containing the mutation was carried out using the primers indicated in Table 2 , FastStart Taq DNA Polymerase (Roche), the Veriti Thermal Cycler (ThermoFisher Scientific) and the PCR program: 94°C 5 min; 94°C 25 s, 55°C 25 s and 72°C 40 s for 38 cycles; and 72°C 7 min. Amplified PCR fragments were sequenced in an ABI3730 sequencer (Applied Biosystems). 
Karyotype analysis
Karyotype analysis of the iPSC line was carried out using cells with more than twenty culture passages which were processed using standard cytogenetic techniques as described (Alonso-Barroso et al., 2017) . At least 35 metaphases were karyotyped.
3.9. DNA fingerprinting analysis DNA fingerprinting analysis was performed as previously described (Alonso-Barroso et al., 2017) .
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.scr.2019.101469. A. López-Márquez, et al. Stem Cell Research 38 (2019) 
